In the global pharmaceutical industry, there were eight M&A deals announced in Q3 2024, worth a total value of $1.3bn, according to GlobalData's Deals Database.

In corporate news, Novo Nordisk A/S (NOVOB.C.DX) surged over +7% after the pharmaceutical giant reported better-than-expected Q3 sales of its popular Wegovy weight-loss drug and narrowed its full-year ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Restaurant Brands International Inc. (T.QSR) (Q3) EPS of $1.30, compared to $1.18 in the prior-year quarter. Novo Nordisk (NYSE: NVO) (Q3) EPS of $3.08, compared to $2.99 in the prior-year quarter.

Bagsværd, Denmark, 7 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated ...

AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy AZN stock as big picture ...

According to a March 2023 study from the Bank of America Institute about consumer spending, seniors born in 1964 or earlier ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

Canadian drugmaker Apotex hired banks to prepare for its IPO. Novo Nordisk reported its net profit in Q3 hit 27.3 billion Danish kroner, just above an aggregate estimate of 26.95 billion Danish kroner ...